HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

((4- (4- amidinophenoxy)butanoyl)aspartyl)valine

structure given in first source

Also Known As:

FK 633; FK-633; FK633

Networked: 6 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - ((4-(4-amidinophenoxy)butanoyl)aspartyl)valine: 6

Experts

1.	Azevedo, Ruben: 1 article (01/2008)
2.	Dietz, Klaus: 1 article (01/2008)
3.	Schiebold, Daniela: 1 article (01/2008)
4.	Straub, Andreas: 1 article (01/2008)
5.	Wendel, Hans Peter: 1 article (01/2008)
6.	Ziemer, Gerhard: 1 article (01/2008)
7.	Arai, Sadahiko: 1 article (08/2004)
8.	Nagamine, Hiroshi: 1 article (08/2004)
9.	Tabata, Shigeki: 1 article (08/2004)
10.	Takemura, Hirofumi: 1 article (08/2004)

Related Diseases

1.	Hemorrhage 02/15/1996 - "Thus, FK633 is a specific GPIIb/IIIa antagonist with potent anti-thrombotic effect in vivo, but careful dosing study might be necessary to avoid the bleeding complications in the clinic." 08/01/2004 - "An ultra-short acting glycoprotein IIb/IIIa antagonist, FK633, is effective in preventing both platelet aggregation and thrombocytopenia during CPB, and may be effective for minimizing postoperative bleeding."
2.	Thrombocytopenia (Thrombopenia) 08/01/2004 - "An ultra-short acting glycoprotein IIb/IIIa antagonist, FK633, is effective in preventing both platelet aggregation and thrombocytopenia during CPB, and may be effective for minimizing postoperative bleeding."
3.	Thrombosis (Thrombus) 02/01/1998 - "Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model." 03/01/1997 - "Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery." 02/15/1996 - "In dogs, bolus injection of FK633 at 0.1 mg/kg significantly suppressed ex vivo ADP-induced platelet aggregation (>40% inhibition) and thrombus formation at stenosed and injured coronary artery, but did not prolong template bleeding time. " 02/01/1998 - "Pretreatment with 0.32 mg/kg i.v. of FK633 significantly prevented occlusive thrombus formation, but aspirin at 10 mg/kg i.v. did not. "
4.	Neointima 03/01/1997 - "These findings suggest that FK633 inhibits platelet activation in the injured artery and improves vascular patency after thrombolysis with tPA with a concomitant suppression of neointima formation."
5.	Vascular System Injuries 03/01/1997 - "When FK633 (0.3 mg/kg/h) was continuously infused i.v. by an implanted osmotic pump for 3, 7 or 14 days after the vascular injury, the neointimal area formation was significantly suppressed in the treatment groups for 7 or 14 days. "

Related Drugs and Biologics

1.	Glycoproteins (Glycoprotein)
2.	Platelet Membrane Glycoproteins
3.	Dihydrotachysterol (AT 10)
4.	Aspirin (Acetylsalicylic Acid)
5.	Adenosine Diphosphate (ADP)
6.	Eptifibatide (Integrilin)
7.	Tirofiban (Aggrastat)